On May, 10 Analysts See $-0.68 EPS for Recro Pharma, Inc. (REPH)

May 3, 2018 - By Anthony Rauscher

Recro Pharma, Inc. (NASDAQ:REPH) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.5. That’s change of 0.15, from 2017Q3’s 1.65. 4 investors sold all, 14 reduced holdings as Recro Pharma, Inc. ratio turned negative. 20 grew positions while 7 funds took positions. Funds hold 9.57 million shares thus 0.59% less from 2017Q3’s 9.63 million shares.
1,196 are owned by Ameritas Investment Prtn. 1.01 million are owned by Alyeska Investment Group Limited Partnership. California Pub Employees Retirement Systems reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). 1,110 are owned by Advisory Svcs Ltd. Broadfin Capital Ltd Liability Corp has invested 3.68% in Recro Pharma, Inc. (NASDAQ:REPH). Deutsche Fincl Bank Ag holds 30,446 shs. Macquarie Ltd, Australia-based fund reported 810 shs. Citigroup Incorporated holds 700 shs or 0% of its capital. Gp Inc owns 9,177 shs. Bb&T Corp invested 0.01% in Recro Pharma, Inc. (NASDAQ:REPH). State Street Corp invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Renaissance Tech Limited, New York-based fund reported 122,000 shs. Meeder Asset Mngmt invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Granite Point Capital Mgmt L P has 0.03% invested in Recro Pharma, Inc. (NASDAQ:REPH). Moreover, Parametric Portfolio Associate Limited Liability Corporation has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH).

Recro Pharma, Inc. registered $3.53 million net activity with 0 buys and 7 selling transactions since December 12, 2017. The insider SCP Vitalife Partners (Israel) II – L.P. sold $13,956. $919,128 worth of Recro Pharma, Inc. (NASDAQ:REPH) was sold by Broadfin Healthcare Master Fund Ltd on Tuesday, December 12. $78,347 worth of stock was sold by Berelowitz Michael on Friday, March 9.

On May, 10. Investors wait Recro Pharma, Inc. (NASDAQ:REPH) to report its quarterly earnings, according to RTT. Analysts have expectation on stock’s EPS of $-0.68. That’s down 61.90 % from last year’s $-0.42 EPS. Analysts at Wall Street see Recro Pharma, Inc.’s 7.94 % negative EPS growth compared to $-0.63 EPS for last quarter. The stock decreased 1.75% or $0.2 during the last trading session, hitting $11.26.Recro Pharma, Inc. has volume of 78,145 shares. Since May 3, 2017 REPH has risen 37.47% and is uptrending. REPH outperformed the S&P 500 by 25.92%.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

In total 4 analysts cover Recro Pharma (NASDAQ:REPH). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. (NASDAQ:REPH) has 100% bullish analysts. 4 are the (NASDAQ:REPH)’s ratings reports on May 3, 2018 according to StockzIntelligence Inc. On Thursday, April 19 the rating was initiated by Berenberg with “Buy”. On Wednesday, February 28 the stock has “Buy” rating by Piper Jaffray. On Thursday, November 9 Roth Capital maintained Recro Pharma, Inc. (NASDAQ:REPH) with “Buy” rating. The company rating was initiated by Oppenheimer on Tuesday, February 13.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States.The company has $219.56 million market cap. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain.Currently it has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.